The emergence of drug-resistant bacteria in the long process of medical and bacterial “games” has cast a shadow over the treatment of infection. The antibacterial “weapons” that were used to be effective are gradually failing, and the “superbacterial” bacteria such as methoxysilincin and carcinoxic intestines are rampant, posing a serious threat to global health, yet the current medical treatment is multi-pronged and “break-up” and seeking solutions.
Precision diagnosis: locking in the “silent” fungus
It is clear that the fungus is the primary link in the antidrug infection. Traditional culture continues to be a cornerstone, with test staff carefully collecting samples of blood, sluice, urine, etc., and placing them in a suitable culture base, patiently waiting for bacteria to “show themselves”, with some slow-growing, harsh conditions for drug-resistant bacteria and new molecular diagnostic techniques. PCR and its derivatives allow rapid detection of bacterial enzymes, precise identification of bacterial species, and the extraction of resistant genes, “tails”, such as detection of genetic mutations associated with tuberculosis cactus resistance, to be known for hours, and to be significantly reduced in the range of “suspicious bacteria”, to help doctors “target” on the start-up line and to select drugs that are not blind.
Development of new antibacterials: exercise of “new weapons”
The research pharmacists are the vanguards of the “failure” and deep-drop in the labs. On the one hand, improving the old drug structure, changing the sidelinks of the drug molecules, the mesmopolitans, improving the prostheses, penetrating force and boosting the fungicides, such as the new hemorrhagic enzyme to the drug-resistant gerrancella, and, on the other hand, digging new antibacterial compounds, “poaching” from marine microorganisms and bacteria in extreme environments, the new antibiotic Tespatine, which has been approved in recent years, has a unique impact target, with a sword slamming the antibacterial cell wall, and placing “fresh blood” in clinical injections, and “wargrounds” of the drug-resistant.
Joint drug use: “Teams”
Single drugs are often “unresponsive” to drug-resistant bacteria, and joint drug use is the preferred tactical choice. Different antibacterial drugs, “joint combat”, such as beta-implamide combinations with beta-implamide inhibitors, enzyme inhibitors, “capable” bacterial resistance “shelter” (enzymes), allow the primary drug to move unobstructedly against the cell wall and treat enzyme-resistant infections; multi-pharmacological complementarities and pharmacokinetic matching teams, taking into account the speed and durability of the bacteria, take into account the whole body and local infection stoves, “cleaning up” clinically for complex resistance to pneumonia, blood flow infections, and, with this precision, “pharmaceutical formula” to contain resistance.
Antibacterial shift program: control of “medicine defence”
Medical institutions run anti-bacterial drug management programmes, and multidisciplinary teams are set up, with specialists such as infectious, pharmaceutical, clinical microbiology units, etc., who are “sitting” at the drug level. Review medical advice for reasonableness, elimination of abuse, misuse, “consultations” on suspected drug-resistant infections, drug-sensitization, choice of medication and course of treatment; medical training, enhanced drug-resistant knowledge, standardized drug-use processes, `classification’ of wards, antibacterial drugs, control of risk of infection, control of resistance from source to source, and development of medical “pharmaceutical veins”.
Sensory control: Cutting off transmission “chain”
Hospitals and communities have worked together to build a strong sense of “wall”. Hospitals have improved environmental clean-up, regular rinsing, spraying of disinfectants, strict sterilization of medical devices and the maintenance of sterile operations at high-frequency contact points in wards, operating rooms, clinics, and clinics. Communities promote good hygiene practices, hand washing, masking and normalization, ventilation in public areas, periodic disinfection, “early sifting, early isolation” of patients infected with drug-resistant bacteria, tracking of contacts, blocking of transmission routes, and “insistence” of drug-resistant bacteria, which, under multi-dimensional “break-up” operations, is expected to break through drug resistance and give priority to the active right to infection.
